Dronedarone in patients with atrial fibrillation
- PMID: 20730005
- PMCID: PMC2922784
- DOI: 10.1007/BF03091794
Dronedarone in patients with atrial fibrillation
Abstract
Dronedarone is a recently developed new class III antiarrhythmic drug which possesses electrophysiological properties of all four Vaughan-Williams classes. An important difference with amiodarone is that it does not contain an iodine component and therefore lacks the iodine-related adverse effects. Based on currently available data, dronedarone can not be recommended as first-line therapy for either rhythm or rate control. We recommend to initiate rhythm or rate control with drugs as indicated in the 2006 guidelines of the ESC and other organisations. As amiodarone, dronedarone can be given to patients for whom standard drug therapy is not effective, or limited by (severe) side effects, although it is less effective than amiodarone. Nevertheless, it may be considered to give dronedarone initially to patients who would otherwise have received amiodarone, since the latter has more severe side effects than the former drug. The daily dosage of dronedarone is oral administration, 400 mg twice daily. Dronedarone is contraindicated in patients with impaired left ventricular function (NYHA class III/IV) and haemodynamic instability. (Neth Heart J 2010;18:370-3.).
Keywords: Donedarone; Amiodarone; Anti-Arrhytmia Agents; Atrial Fibrillation.
Similar articles
-
Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.Cardiol Rev. 2009 Sep-Oct;17(5):230-4. doi: 10.1097/CRD.0b013e3181b15ab9. Cardiol Rev. 2009. PMID: 19690474 Review.
-
Dronedarone.Drugs Today (Barc). 2011 Feb;47(2):109-33. doi: 10.1358/dot.2011.47.2.1545699. Drugs Today (Barc). 2011. PMID: 21431100 Review.
-
Dronedarone: a new antiarrhythmic agent.Pharmacotherapy. 2010 Sep;30(9):904-15. doi: 10.1592/phco.30.9.904. Pharmacotherapy. 2010. PMID: 20795846 Review.
-
Dronedarone: an emerging therapy for atrial fibrillation.Ther Adv Cardiovasc Dis. 2010 Jun;4(3):155-64. doi: 10.1177/1753944710366266. Epub 2010 Apr 23. Ther Adv Cardiovasc Dis. 2010. PMID: 20418270 Review.
-
Dronedarone: an emerging agent with rhythm- and rate-controlling effects.J Cardiovasc Electrophysiol. 2006 Sep;17 Suppl 2:S17-20. doi: 10.1111/j.1540-8167.2006.00583.x. J Cardiovasc Electrophysiol. 2006. PMID: 16939434 Review.
Cited by
-
[How to: clinical use of antiarrhythmic drugs].Herzschrittmacherther Elektrophysiol. 2023 Mar;34(1):82-90. doi: 10.1007/s00399-022-00919-y. Epub 2023 Jan 24. Herzschrittmacherther Elektrophysiol. 2023. PMID: 36692540 Review. German.
References
-
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006;27:1979-2030. - PubMed
-
- Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6:228-36. - PubMed
-
- Chan AL, Hsieh HJ, Hsieh YA, Lin SJ. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther. 2008;46:96-101. - PubMed
-
- Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31:127-41. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials